西妥昔单抗和贝伐单抗在晚期结直肠癌一二线治疗中的研究进展

Abstract
Figure/Table
References (25)
Related Citation (1)

Download: PDF (690 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract In China, the incidence of CRC is reportedly increasing over time. The treatment options including surgery, chemotherapy and radiotherapy, which are available depending mostly on disease stage. However, patients with advanced CRC have lost the chance of surgery，may also have a worse life because of chemotherapy and radiotherapy. With more and more studies on targeted therapy, such as Bevacizumab and Cetuximab, may shines a light for the patients with CRC. Chemotherapy combined with targeted therapy has become a new direction for the treatment of advanced CRC. Moreover, the association between tumor location and targeted therapy has become a hot topic. This review focuses on the progress of monoclonal antibody in the first-and second-tier treatment of advanced CRC and the effect of the left and right half colon on the efficacy of targeted drugs.

Key words： Advanced colorectal cancer Cetuximab Bevacizumab

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DUAN Jiawen1 WU Xueliang1 NIU Yuchun2 QU Ming1 XUE Jun1

Cite this article:

DUAN Jiawen1 WU Xueliang1 NIU Yuchun2 QU Ming1 XUE Jun1. Research progress on Cetuximab and Bevacizumab in first and second-line treatment on advanced colorectal cancer[J]. 中国医药导报, 2017, 14(24): 50-53.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I24/50

[1] László L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer [J]. Magy Onkol，2010，54（4）：383-394.
[2] Chen WQ，Zeng HM，Zheng ＲS，et al. Cancer incidenceand mortality in China，2007 [J]. Chin J Cancer Ｒes，2012， 24（1）∶1-8.
[3] Gibson ＲJ，Keefe DM，Lalla ＲV，et al. Systematic review ofagents for the management of gastrointestinal mucositis in cancerpatients [J]. Support Care Cancer，2013，21（1）：313-326.
[4] Tabernero J，Yoshino T，Cohn AL，et al. Ramucirumab versus placebo in combination with second—line FOI. FIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab，oxaliplatin，and a fluoropyrimi dine（RAISE）：a randomised，double-blind，multicentre，phase 3 study [J]. Lancet Oncol，2015，16（5）：499-508.
[5] Saltz LB，Meropol NJ，Loehrer PJ Sr，et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. [J]. J Clin Oncol，2004，22（7）：1201-1208.
[6] Li S，Schmitz KR，Jeffrey PD，et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab [J]. Cancer Cell，2005，7（4）：301-311.
[7] Venook A，Niedzwiecki D，Hollis D，et al. Phase Ⅲ study of irinotecan/5FU/LV （FOLFIRI） or oxaliplatin/5FU/LV（FOLFOX）± cetuximab for patients（pts）with untreated metastatic adenocarcinoma of the colon or rectum（MCRC）：CALGB 80203 preliminary results [J]. J Clin Oncol， 2006，24（18s）：3509.
[8] VanCutsem E，Nowacki M，Lang I，et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer：the CRYSTAL trial [J]. J Clin Oncol，2007， 25（11）：4000-4010.
[9] Maughan TS，Adams RA，Smith CG，et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer：results of the randomised phase 3 MRC COIN trial [J]. Lancet，2011，377（9783）：2103-2114.
[10] Cunningham D，Humblet Y，Siena S，et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan—refractory metastatic colorectal cancer [J]. N Engl J Med，2004，351（3）：337-345.
[11] Sobrero AF，Maurel J，Fehrenbacher B，et al. EPIC：phase Ⅲ trial ofcetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol，2008，26（22）：2311-2319.
[12] Iwamoto S，Hazama S，Kato T，et al. Multicenter phase II study of second-line cetuximab plas folinic acid/5-fluoroura-cil/irinotecan（FOLFIRI）in KRAS wild-type metastatic colorectal cancer：the FLIER study [J]. Anticancer Res，2014，34（14）：1967-1973.
[13] Samelis GF，Ekmektzoglou KA，Tsiakou A，et al. The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit [J]. Hepatogastroenterology，2011，58（112）：1968-1971.
[14] Hurwitz H，Fehrenbacher L，Novotny W，et al. Bevacizumab plus irinotecan，fluorouracil，and leucovorin formetastatic colorectal cancer [J]. N Engl J Med，2004，350（23）：2335-2342.
[15] Vieitez J，Fonseca P，Crespo G，et al. Results of a phase Ⅱ study of capecitabine，CPT-11（CAPIRI）and bevaci-zumab in chemotherapy-na ve stage Ⅳ colorectal cancer patients [C]. Asco GI，2009.
[16] Hochster HS，Hart LL，Ramanathan RK，et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer： results of the tree study [J]. J Clin Oncol，2008，26（21）：3523-3529.
[17] Guan ZZ，Xu JM，Luo RC，et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer：a randomized phase Ⅲ artist trial [J]. Chin J Cancer，2011，30（10）：682-689.
[18] Fuchs CS，Marshall J，Mitchell E，et al. Randomized，controlled trial of irinotecan plus infusional，bolus，or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer：results from the BICC-C Study [J]. J Clin Oncol，2007，25（30）：4779-4786.
[19] Giantonio BJ，Catalano PJ，Meropol NJ，et al. Bevacizumab in combination with oxaliplatin，fluorouracil，and leucovorin（FOLFOX4）for previously treated metastatic colorectal cancer：results from the Eastern Cooperative Oncology Group Study E3200 [J]. J Clin Oncol，2007，25（12）：1539-1544.
[20] Dirk A，Thierry A，Jaafar B，et al. Bevacizumab （BEV） plus chemotherapy（CT）continued beyond first progression in patients with metastatic colorectal cancer（m CRC）previously treated with BEV plus CT：results of a randomized phase Ⅲ intergroup study（TML study）[J]. J Clin Oncol，2012，30（18）：CRA 3503.
[21] Heinemann V，Von Weikersthal LF，Decker T，et al. Randomized comparison of FOLFIRI plus cetuximab versus FOL-FIRI plus bevacizumab as first-line treatment of KRAS wild-typemetastatic colorectal cancer：German AIO study KRK-0306（FIRE-3）[J]. J Clin Oncol，2013，31（Suppl）：3506.
[22] Formica V，Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer [J]. World J Gastroenterol，2015，21（10）：2871-2874.
[23] Venook A，Dnieozwiecki，Lenz HJ，et al. CALGB/SWOG80405L：Phase Ⅲ trial of irinotecan/5-FU/leucovorin（FOLFIRI or oxaliplatin/5-FU/leucovorin （m FOLFOX6）with bevacizumab（BV）or cetuximab（CET）for patients（pts）with KRAS wild-type（wt）untreated metastatic ade-nocarcinoma of the colon or rectum （MCRC）[J].J Clin Oncol，2015，32：5s.
[24] Campana JP，Pellegrini PA，Rossi GL，et al. Right versus left laparoscopic colectomy for colon cancer：does side make any difference [J]. Int J Colorectal Dis，2017,32（6）：907-912.
[25] Chen G. Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer [J]. Zhonghua Wei Chang Wai Ke Za Zhi，2017，20（1）：28-33.